All In Biotech

NDA 020576 · Recordati Rare

Cystadane

Betaine · Oral · Methylating Agent

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Oct 25, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

29

6 Phase 3, 3 recruiting

FAERS reports

1,045

656 serious, 74 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

CYSTADANE ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are ( 1 ): Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 25, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • CYSTADANE · BETAINE 1GM/SCOOPFUL · FOR SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betaine" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use149
  • overdose86
  • vomiting81
  • diarrhoea64
  • product dose omission55
  • nausea48
  • seizure43
  • product use issue41
  • pneumonia39
  • product dose omission issue39
  • pyrexia39
  • inappropriate schedule of product administration37

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
20062
20084
20093
20105
20118
201224
201314
201435
201539
201685
201772
201883
2019122
2020123
202165
202284
2023118
202464
202560
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cystadane (Betaine)

2024 spending

$1.1M

Beneficiaries

74

679 claims

Per beneficiary

$14,976

$4.67 per unit

View as table
YearSpending
2020$3,490,250
2021$3,813,679
2022$4,191,100
2023$2,900,642
2024$1,108,241

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 328 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.